WOLFGANG WINKELMAYER to Darbepoetin alfa
This is a "connection" page, showing publications WOLFGANG WINKELMAYER has written about Darbepoetin alfa.
Connection Strength
1.163
-
Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med. 2021 04 29; 384(17):1589-1600.
Score: 0.201
-
Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 04 29; 384(17):1601-1612.
Score: 0.201
-
Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Am J Kidney Dis. 2015 Jul; 66(1):106-13.
Score: 0.133
-
Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Am J Kidney Dis. 2015 Jul; 66(1):69-74.
Score: 0.130
-
Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). JAMA Intern Med. 2014 May; 174(5):699-707.
Score: 0.124
-
What caused excess strokes in patients randomized to darbepoetin in the trial to reduce cardiovascular events with Aranesp therapy (TREAT)?: no smoking gun. Circulation. 2011 Dec 20; 124(25):2805-8.
Score: 0.105
-
Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting. J Am Soc Nephrol. 2011 Jan; 22(1):1-2.
Score: 0.098
-
Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis. Nephrol Dial Transplant. 2023 09 29; 38(10):2358-2367.
Score: 0.059
-
Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials. Am J Nephrol. 2022; 53(10):701-710.
Score: 0.056
-
Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. Am J Hematol. 2022 09; 97(9):1178-1188.
Score: 0.055